Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01693692 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of TD-9855 to Treat Fibromyalgia
A Phase 2 study, sponsored by Theravance Biopharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 392
- Enrollment target
NCT01693692 is a Phase 2 study that has completed, run by Theravance Biopharma. The registered enrollment target is 392 participants.
The verdict
NCT01693692, a Phase 2 study, has completed, sponsored by Theravance Biopharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 392 participants
- Enrollment target
Study Summary
The purpose of this study study is to determine whether TD-9855 is effective in treating patients with fibromyalgia.
Interventions
- DRUG Placebo
- DRUG TD-9855 Group 1
- DRUG TD-9855 Group 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 392 participants |
| Start Date | 2012-11 |
| Est. Completion | 2014-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01693692
The ClinicalTrials.gov registry entry for NCT01693692 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 392 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theravance Biopharma, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01693692 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01693692 about?
NCT01693692 is a clinical study titled "Phase 2 Study of TD-9855 to Treat Fibromyalgia". The purpose of this study study is to determine whether TD-9855 is effective in treating patients with fibromyalgia.
What is the current status of trial NCT01693692?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 392 participants. The study started on 2012-11. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01693692?
The interventions under investigation include: Placebo (DRUG), TD-9855 Group 1 (DRUG), TD-9855 Group 2 (DRUG).
Who is sponsoring clinical trial NCT01693692?
This trial is sponsored by Theravance Biopharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.